Ida D’Onofrio

[Neil D. Gross, MD, FACS @DrNeilGross]

The standard of care has finally changed for patients with resectable head and neck #cancer!! Congratulations @DrUppaluri and all the #KN-689 investigators.

https://t.co/DE3U7kBH3m

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

#AIRO2023 is about to begin. Join us in Bologna, from 27th to 29th of October.

AIRO Head and Neck Study Group meeting on the 27th, from 1.00pm to 2.20 pm.

More info https://t.co/qKFsz0t2st

Full scientific program https://t.co/5FV7a6iGQu

Registrations https://t.co/geHsxtyN09

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

132 pts randomly assigned to standard IMRT vs weekly replanned IMRT.
No benefit in terms of PRO or salivary flows at 12 months.
Possible limitation: minimized parotid dose but not SMGs or oral cavity dose.

#radonc
#hnscm
https://t.co/G1VQZwe1GA

[Ida D’Onofrio @IdaDonofrio]

Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy–A Substudy From TROG12.01 https://t.co/lquNIeC3iM

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

24.6.22 Corso gratuito "Current Management and Future Challenges in Salivary Glands Cancer". 6 ECM, in presenza (max 40) e online.
Registrazioni entro 20/6/22: https://t.co/nVQT84UuY7
Info: https://t.co/DyuLcNOVBm
@Fond_CNAO

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

It's hard to summarize the brilliant lecture from Dr. Riaz. Intra-treatment imaging, cfDNA, pre-therapy anti-tumor immunity and viral agents could lead the way to de-escalation in HNSCC. Total dose of 30 Gy + cisplatin sounds very interesting. Back from #ESTRO2022

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Back from #ESTRO2022. Interesting lecture from Dr. Thariat: in PORT, no need to sistematically cover the entire flap with >60 Gy. Cover the junction areas. Under investigation the spare of the inner portion

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Back from #ESTRO2022. Beautiful lecture from Dr. Langendijk about radiation induced toxicity in oral cavity PORT. Limiting target volumes and new radiation techniques could help reduce toxicities. Spare the oral cavity!

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Deintensification in HPV+ HNSCC. We're not there yet, but we carry on. Have we got a long way to go? Meanwhile, SOC is still full dose RT + CDDP. Very interesting mise à jour from Dr. Blanchard. Back from #ESTRO2022

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Back from #ESTRO2022. Dr. Budach about CTV in PORT with flap. Lack of data: patterns of recurrence, depth of infiltration and interval between Sx and PORT, flap types and probability of cancer infiltration. 3-6 mm of the flap should be included if Rclose

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Aperte le iscrizioni al corso di contouring dei carcinomi della cute H&N.
https://t.co/l13csVsv3e

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Excellent oncological outcomes for both arms, slightly better QoL with RT.
Selection and intervention biases: 88% p16+ patients, 71% of TORS arm had adj RT.
Data that could help decision-making process in multidisciplinary tumor board.
https://t.co/ZbjARP3EKa